244 related articles for article (PubMed ID: 37226522)
1. The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease.
Gupta N; Papasotiriou S; Hanauer S
Expert Rev Clin Immunol; 2023; 19(9):1075-1089. PubMed ID: 37226522
[TBL] [Abstract][Full Text] [Related]
2. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease.
Macaluso FS; Rodríguez-Lago I
Curr Drug Metab; 2020; 21(4):247-255. PubMed ID: 32156234
[TBL] [Abstract][Full Text] [Related]
3. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
Núñez P; Quera R; Yarur AJ
Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
[TBL] [Abstract][Full Text] [Related]
4. JAK selectivity: more precision less troubles.
Roda G; Dal Buono A; Argollo M; Danese S
Expert Rev Gastroenterol Hepatol; 2020 Sep; 14(9):789-796. PubMed ID: 32520647
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
D'Amico F; Fiorino G; Furfaro F; Allocca M; Danese S
Expert Opin Investig Drugs; 2018 Jul; 27(7):595-599. PubMed ID: 29938545
[TBL] [Abstract][Full Text] [Related]
6. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease.
Hernandez-Rocha C; Vande Casteele N
Curr Opin Pharmacol; 2020 Dec; 55():99-109. PubMed ID: 33207299
[TBL] [Abstract][Full Text] [Related]
7. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Kim JW; Kim SY
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768752
[TBL] [Abstract][Full Text] [Related]
8. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
10. Prioritization in inflammatory bowel disease therapy.
Herrlinger KR; Stange EF
Expert Rev Gastroenterol Hepatol; 2023; 17(8):753-767. PubMed ID: 37480322
[TBL] [Abstract][Full Text] [Related]
11. JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications.
Agrawal M; Kim ES; Colombel JF
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S755-S760. PubMed ID: 32006031
[TBL] [Abstract][Full Text] [Related]
12. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
Nakase H
Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.
Cordes F; Foell D; Ding JN; Varga G; Bettenworth D
World J Gastroenterol; 2020 Jul; 26(28):4055-4075. PubMed ID: 32821070
[TBL] [Abstract][Full Text] [Related]
14. Update for surgeons on novel induction treatments for acute severe inflammatory bowel disease associated colitis.
Levar T; Johnston M; Ding NS; Behrenbruch C
ANZ J Surg; 2024 May; 94(5):795-803. PubMed ID: 38450582
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports.
Momen Majumder MS; Haq SA; Rasker JJ
J Med Case Rep; 2023 Mar; 17(1):71. PubMed ID: 36855206
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
Solitano V; Vuyyuru SK; MacDonald JK; Zayadi A; Parker CE; Narula N; Peyrin-Biroulet L; Danese S; Feagan BG; Singh S; Ma C; Jairath V
J Crohns Colitis; 2023 Nov; 17(11):1800-1816. PubMed ID: 37317532
[TBL] [Abstract][Full Text] [Related]
17. Upadacitinib in Crohn's disease.
Dignass A; Esters P; Flauaus C
Expert Opin Pharmacother; 2024 Mar; 25(4):359-370. PubMed ID: 38512115
[TBL] [Abstract][Full Text] [Related]
18. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
20. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Salas A; Hernandez-Rocha C; Duijvestein M; Faubion W; McGovern D; Vermeire S; Vetrano S; Vande Casteele N
Nat Rev Gastroenterol Hepatol; 2020 Jun; 17(6):323-337. PubMed ID: 32203403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]